Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo for Recombinant Human Growth Hormone Clear all
Completed Phase 2 Interventional Results available

Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.

NCT00766038
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Recombinant human Growth Hormone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Bakersfield, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 2, 2026, 4:12 AM EDT
Terminated Phase 4 Interventional Results available

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

NCT00328926
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
Luveris® 75 IU, Luveris® 25 IU, Placebo, Recombinant human follicle stimulating hormone (r-hFSH), Recombinant human chorionic gonadotropin (r-hCG)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 2, 2026, 4:12 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

NCT01220128
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A, Placebo, Aromatase inhibitor, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Trastuzumab
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Newark, Delaware • Plantation, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 1 Interventional

Growth Hormone Administration and the Human Immune System

NCT00663611
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Norditropin, Placebo
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
25 Years to 50 Years · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 2 Interventional Results available

Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa

NCT00283595
View directory record Official record
Conditions
Anorexia Nervosa, Osteopenia, Osteoporosis, Eating Disorders
Interventions
Recombinant Human Growth Hormone, Placebo for Recombinant Human Growth Hormone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 45 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 2, 2026, 4:12 AM EDT
Terminated Phase 3 Interventional Results available

Study of TV-1106 in Growth Hormone-Deficient Adults

NCT02410343
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
TV-1106, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
25
States / cities
Artesia, California • Fountain Valley, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome

NCT01077960
View directory record Official record
Conditions
Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Interventions
Serostim
Biological
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Palm Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 2, 2026, 4:12 AM EDT
Recruiting Phase 3 Interventional

Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)

NCT04867317
View directory record Official record
Conditions
Adult Growth Hormone Deficiency, Mild Traumatic Brain Injury
Interventions
Somatropin, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 55 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Not applicable Interventional Results available

Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency

NCT00182091
View directory record Official record
Conditions
Acromegaly, Growth Hormone Deficiency, Pituitary Disease
Interventions
Recombinant human growth hormone, Saline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients

NCT00082628
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Placebo, Serostim® 4 mg, Serostim® 2 mg
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)

NCT00915954
View directory record Official record
Conditions
Acromegaly, Type 2 Diabetes Mellitus
Interventions
Oral Glucose Tolerance Test, Subcutaneous administration of recombinant human IGF-1, Placebo
Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

NCT00130286
View directory record Official record
Conditions
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X, Body Weight Changes
Interventions
Rosiglitazone, Recombinant human growth hormone + rosiglitazone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 2, 2026, 4:12 AM EDT
Withdrawn Phase 2 Interventional

Growth Hormone and Exclusion Diet Therapy in Juvenile Crohn's Disease

NCT01647412
View directory record Official record
Conditions
Crohn's Disease
Interventions
Growth Hormone, Nutraceutical Combination, Exclusion Diet, Placebo Growth Hormone
Drug · Dietary Supplement · Other
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 2, 2026, 4:12 AM EDT
Terminated Phase 2Phase 3 Interventional

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

NCT00675714
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion Study, Collection of blood and tissues, Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI, Humatrope, Ketoconazole, Oxandrolone, Propranolol, Oxandrolone and propranolol combined, Humatrope and propranolol combined, Placebo, Exercise--Hospital supervised intensive exercise program, Home exercise program
Procedure · Drug · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 80 Years
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 1 Interventional

Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI)

NCT02114775
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Growth Hormone, Sildenafil, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 2, 2026, 4:12 AM EDT